AARD

AARD Earnings Preview

Aardvark Therapeutics, Inc. · Healthcare · $122M

14d until earnings

AARD Earnings

Thursday, May 14 2026
EPS Estimate
$-0.91
$-1.49 – $-0.75
Current Price
$5.59

Our Position

bearish · high

Phase 3 trial pause tanks stock 53.56% in one day

structured data est. revisions falling (-2.6pp / 30d)

A Phase 3 pause is clinical catastrophe territory. The trial was likely the cornerstone of near-term value; without it, the company has no near-term value catalyst and faces a multi-year reset if the trial resumes at all. Investors are pricing in worst-case scenarios until management clarifies the pause reason.

Watch: Watch for an SEC filing or investor call explaining the pause rationale and expected timeline for resumption or discontinuation. Safety data becomes the critical variable — any hint of adverse events will keep the stock under pressure.

Data Signal Summary

1 bullish
3 bearish
Estimates down -2% Insider buying cluster Put/call 2.3 (bearish skew) Price downtrend

Key Context

Insider Activity
buying
Price Trend
downtrend
From 52w High
-1.1%
Est. Revisions (30d)
-2.5% 2up/0dn
Analyst Target (mean)
$17 $6–$45 +202%
Options P/C Ratio
2.31
Est. Dispersion
81% 8 analysts
Insider Cluster
strong buy (officer)
Fund Convergence
moderate Citadel, Two Sigma

Recent Activity

insider trades 18 transactions
Buy · LEE TIEN-LI (Chief Executive Officer) ·7,000 shares ·$101,395
Buy · SUN NELSON B. (Chief Financial Officer) ·3,000 shares ·$43,200
Exercise · LEE TIEN-LI (Chief Executive Officer) ·1,229 shares ·$5,211
Exercise · JONES BRYAN (Chief Operating Officer) ·1,250 shares ·$5,300
Buy · LEE TIEN-LI (Chief Executive Officer) ·10,000 shares ·$96,624
13 more
Buy · LEE TIEN-LI ·20,000 shr ·$160,654
Buy · SUN NELSON B. ·6,000 shr ·$48,440
Exercise · LEE TIEN-LI ·17,209 shr ·$72,966
Buy · CORMORANT ASSET MANAGEMENT ,L.P ·187,500 shr ·$2,493,750
Other · CORMORANT ASSET MANAGEMENT ,L.P ·800,189 shr
Other · VICKERS VENTURE FUND VI PTE, LTD. ·2,050,902 shr
Buy · DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P. ·1,250,000 shr ·$16,625,000
Other · DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P. ·2,667,299 shr
Buy · LEE TIEN-LI ·16,542 shr ·$220,009
Other · LEE TIEN-LI ·41,303 shr
Other · CHI JEFFREY CHIEN CHUEN PH.D. ·133,364 shr
Buy · SUN NELSON B. ·10,000 shr ·$133,000
Other · SUN NELSON B. ·7,001 shr